SAFETY AND EFFICACY OF INTRAVITREAL BEVACIZUMAB (AVASTIN) FOR THE MANAGEMENT OF BRANCH AND HEMIRETINAL VEIN OCCLUSION
暂无分享,去创建一个
P. Rosenfeld | W. Feuer | H. Flynn | C. Puliafito | A. Berrocal | N. Gregori | S. G. Schwartz | S. Dubovy | T. Murray | W. Smiddy | Wen-Hsiang Lee | G. H. Rattan | L. Al-Attar
[1] A. Barone,et al. BEVACIZUMAB COMPARED WITH MACULAR LASER GRID PHOTOCOAGULATION FOR CYSTOID MACULAR EDEMA IN BRANCH RETINAL VEIN OCCLUSION , 2009, Retina.
[2] U. Schmidt-Erfurth,et al. Intraocular concentrations of growth factors and cytokines in retinal vein occlusion and the effect of therapy with bevacizumab. , 2009, Investigative ophthalmology & visual science.
[3] J. Jonas,et al. Early Intravitreal Bevacizumab for Non-Ischaemic Branch Retinal Vein Occlusion , 2008, Ophthalmologica.
[4] U. Schmidt-Erfurth,et al. Intravitreal bevacizumab (Avastin®) for macular oedema secondary to retinal vein occlusion: 12-month results of a prospective clinical trial , 2008, British Journal of Ophthalmology.
[5] S. Wolf,et al. Treatment of Branch Retinal Vein Occlusion induced Macular Edema with Bevacizumab , 2008, BMC ophthalmology.
[6] V. Brar,et al. Spectral Domain OCT Documented Resolution of Recalcitrant Macular Edema after Intravitreal Bevacizumab in Branch Retinal Vein Occlusion , 2008, European journal of ophthalmology.
[7] S. Sadda,et al. Effects on the contralateral eye after intravitreal bevacizumab and ranibizumab injections: a case report. , 2008, Annals of the Academy of Medicine, Singapore.
[8] S. C. Lee,et al. Prognostic factors for visual outcome after intravitreal bevacizumab for macular edema due to branch retinal vein occlusion , 2008, Graefe's Archive for Clinical and Experimental Ophthalmology.
[9] F. Badalà. The treatment of branch retinal vein occlusion with bevacizumab , 2008, Current opinion in ophthalmology.
[10] S. Bakri,et al. Intravitreal bevacizumab for macular oedema secondary to branch retinal vein occlusion , 2008, Eye.
[11] L. Yannuzzi,et al. COMPARISON OF TWO DOSES OF INTRAVITREAL BEVACIZUMAB (AVASTIN) FOR TREATMENT OF MACULAR EDEMA SECONDARY TO BRANCH RETINAL VEIN OCCLUSION: Results From the Pan-American Collaborative Retina Study Group at 6 Months of Follow-Up , 2008, Retina.
[12] W. Freeman,et al. Comparison of visual acuity in macular degeneration patients measured with snellen and early treatment diabetic retinopathy study charts. , 2008, Ophthalmology.
[13] U. Schmidt-Erfurth,et al. Intravitreal Avastin for macular oedema secondary to retinal vein occlusion: a prospective study , 2008, British Journal of Ophthalmology.
[14] S. Priglinger,et al. Intravitreal bevacizumab for the treatment of macular oedema secondary to branch retinal vein occlusion , 2008, British Journal of Ophthalmology.
[15] K. Bartz-Schmidt,et al. One-year results after intravitreal bevacizumab therapy for macular edema secondary to branch retinal vein occlusion , 2008, Graefe's Archive for Clinical and Experimental Ophthalmology.
[16] M. Maia,et al. Primary intravitreal bevacizumab for the management of pseudophakic cystoid macular edema: Pilot study of the Pan‐American Collaborative Retina Study Group , 2007, Journal of cataract and refractive surgery.
[17] S. Byeon,et al. Short-term results of intravitreal bevacizumab for macular edema with retinal vein obstruction and diabetic macular edema. , 2007, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.
[18] M. Maia,et al. Twelve-month safety of intravitreal injections of bevacizumab (Avastin®): results of the Pan-American Collaborative Retina Study Group (PACORES) , 2007, Graefe's Archive for Clinical and Experimental Ophthalmology.
[19] A. K. Chung,et al. Photodynamic therapy for angioid streaks. , 2007, Ophthalmology.
[20] R. Avery,et al. INTRAVITREAL BEVACIZUMAB (AVASTIN) IN THE TREATMENT OF MACULAR EDEMA SECONDARY TO BRANCH RETINAL VEIN OCCLUSION , 2007, Retina.
[21] L. Yannuzzi,et al. REBOUND MACULAR EDEMA FOLLOWING BEVACIZUMAB (AVASTIN) THERAPY FOR RETINAL VENOUS OCCLUSIVE DISEASE , 2007, Retina.
[22] K. Schaal,et al. [Central and branch retinal vein occlusion. Current strategies for treatment in Germany, Austria and Switzerland]. , 2007, Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft.
[23] A. Höh,et al. Retinale Zentralvenen- und Venenastverschlüsse , 2007, Der Ophthalmologe.
[24] F. Schütt,et al. Bevacizumab zur Therapie des Makulaödems infolge venöser retinaler Gefäßverschlüsse , 2007, Der Ophthalmologe.
[25] N. Yadav,et al. Clinical, anatomic, and electrophysiologic evaluation following intravitreal bevacizumab for macular edema in retinal vein occlusion. , 2007, American journal of ophthalmology.
[26] H. Agostini,et al. Bevacizumab in retinal vein occlusion-results of a prospective case series , 2007, Graefe's Archive for Clinical and Experimental Ophthalmology.
[27] Jennifer I. Lim,et al. Relationship between optical coherence tomography-measured central retinal thickness and visual acuity in diabetic macular edema. , 2007, Ophthalmology.
[28] I. Scott,et al. INTRAVITREAL BEVACIZUMAB (AVASTIN) FOR CENTRAL AND HEMICENTRAL RETINAL VEIN OCCLUSIONS: IBeVO Study , 2007, Retina.
[29] J. Jonas,et al. Intravitreal bevacizumab for branch retinal vein occlusion. , 2006, Acta ophthalmologica Scandinavica.
[30] P. Rosenfeld,et al. ONE-YEAR SAFETY AND EFFICACY OF INTRAVITREAL TRIAMCINOLONE ACETONIDE FOR THE MANAGEMENT OF MACULAR EDEMA SECONDARY TO CENTRAL RETINAL VEIN OCCLUSION , 2006, Retina.
[31] V. Sundaram,et al. Intravitreal triamcinolone for the treatment of ischemic macular edema associated with branch retinal vein occlusion. , 2006, American journal of ophthalmology.
[32] Sander R. Dubovy,et al. SHORT-TERM SAFETY AND EFFICACY OF INTRAVITREAL BEVACIZUMAB (AVASTIN) FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION , 2006, Retina.
[33] P. Rosenfeld,et al. Tolerability and efficacy of multiple escalating doses of ranibizumab (Lucentis) for neovascular age-related macular degeneration. , 2006, Ophthalmology.
[34] P. Szurman,et al. [Bevacizumab for treatment of macular edema secondary to retinal vein occlusion]. , 2006, Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft.
[35] Michael D. Ober,et al. INTRAVITREAL TRIAMCINOLONE INJECTION FOR TREATMENT OF MACULAR EDEMA SECONDARY TO BRANCH RETINAL VEIN OCCLUSION , 2005, Retina.
[36] P. Rosenfeld,et al. Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for macular edema from central retinal vein occlusion. , 2005, Ophthalmic surgery, lasers & imaging : the official journal of the International Society for Imaging in the Eye.
[37] H. Yamashita,et al. Intravitreal levels of vascular endothelial growth factor and interleukin-6 are correlated with macular edema in branch retinal vein occlusion , 2006, Graefe's Archive for Clinical and Experimental Ophthalmology.
[38] J. Garcia-Arumi,et al. MANAGEMENT OF MACULAR EDEMA IN BRANCH RETINAL VEIN OCCLUSION WITH SHEATHOTOMY AND RECOMBINANT TISSUE PLASMINOGEN ACTIVATOR , 2004, Retina.
[39] J. Holladay,et al. Visual acuity measurements. , 2004, Journal of cataract and refractive surgery.
[40] M. M. Ballús,et al. Management of macular edema in branch retinal vein occlusion with sheathotomy and recombinant tissue plasminogen activator , 2004 .
[41] Thomas J Liesegang,et al. Safe and effective. , 2003, Ophthalmology.
[42] Ingrid U Scott,et al. Vitreoretinal surgery for complications of branch retinal vein occlusion , 2002, Current opinion in ophthalmology.
[43] G. Lutty,et al. Pathologic features of vascular endothelial growth factor-induced retinopathy in the nonhuman primate. , 2002, American journal of ophthalmology.
[44] G F Vrensen,et al. Endothelial cell hypertrophy induced by vascular endothelial growth factor in the retina: new insights into the pathogenesis of capillary nonperfusion. , 2001, Archives of ophthalmology.
[45] R A Bruce,et al. Surgical decompression of branch retinal vein occlusion via arteriovenous crossing sheathotomy: a prospective review of 15 cases. , 1999, Retina.
[46] M. Goldberg,et al. Laser-induced chorioretinal venous anastomosis for nonischemic central or branch retinal vein occlusion. , 1998, Archives of ophthalmology.
[47] P. Campochiaro,et al. Intravitreal sustained release of VEGF causes retinal neovascularization in rabbits and breakdown of the blood-retinal barrier in rabbits and primates. , 1998, Experimental eye research.
[48] Joan W. Miller,et al. Intravitreous injections of vascular endothelial growth factor produce retinal ischemia and microangiopathy in an adult primate. , 1996, Ophthalmology.
[49] E S Gragoudas,et al. Inhibition of vascular endothelial growth factor prevents retinal ischemia-associated iris neovascularization in a nonhuman primate. , 1996, Archives of ophthalmology.
[50] E. Keshet,et al. Hypoxia-induced expression of vascular endothelial growth factor by retinal cells is a common factor in neovascularizing ocular diseases. , 1995, Laboratory investigation; a journal of technical methods and pathology.
[51] G. Sanborn,et al. Progressive capillary nonperfusion in temporal branch retinal vein obstruction. , 1989, Annals of ophthalmology.
[52] L. Hansen,et al. [Randomized study of the effect of isovolemic hemodilution in retinal branch vein occlusion]. , 1988, Fortschritte der Ophthalmologie : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft.
[53] R. Danis,et al. Microvascular changes in experimental branch retinal vein occlusion. , 1987, Ophthalmology.
[54] D. Finkelstein,et al. Argon laser photocoagulation for macular edema in branch vein occlusion. , 1986, Ophthalmology.
[55] Argon laser photocoagulation for macular edema in branch vein occlusion. The Branch Vein Occlusion Study Group. , 1984, American journal of ophthalmology.